ArticleJournal of thoracic disease2026
Prevalence and clinical outcomes of anaplastic lymphoma kinase rearrangements in surgically resected adenocarcinoma lung cancer: a retrospective cohort study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The recent expansion of anaplastic lymphoma kinase (ALK)-targeted therapies into curative-intent settings is a major advance in the management of ALK-rearranged lung adenocarcinomas. However, real-world data on the prevalence and postoperative outcome reflecting this shift are needed to establish clinical baselines. This study aimed to characterize the prevalence, recurrence patterns, and prognostic factors of ALK-positive lung cancer in a modern surgical cohort. Methods: We conducted a single-center, retrospective cohort study of 5,783 patients with pathological stage I-III non-small cell lung cancer (NSCLC) who underwent curative-intent resection. Among the 3,288 patients with resected lung adenocarcinoma who underwent ALK testing, ALK prevalence and postoperative outcomes, including disease-free survival (DFS) and recurrence patterns, were evaluated. A multivariate Cox regression analysis was used to identify factors associated with recurrence. Results: ALK rearrangements were identified in 150 of 3,288 patients (4.6%). The median age was 56 years; 60.7% were never-smokers and 56.0% were female. Most patients had stage I disease (58.0%) and 30.0% had stage III disease. At a median follow-up of 45.7 months, the median DFS was not reached, and the 1-, 3-, and 5-year DFS rates were 93.3%, 77.6%, and 65.7%, respectively. N2 nodal involvement was the strongest independent predictor of recurrence [hazard ratio (HR), 14.64; 95% confidence interval (CI): 4.59-46.76; P<0.001]. Distant recurrence was predominant (81.1%), with the brain being the most frequent site (29.7%). Overall survival (OS) data were immature, with one death (0.7%) observed during follow-up. Conclusions: ALK rearrangements represent a clinically meaningful subset of resectable lung adenocarcinomas, supporting routine molecular testing even in early-stage disease. Recurrence risk is primarily driven by nodal burden, particularly N2 disease, and is characterized by frequent distant and intracranial recurrences. These findings define the postoperative risk landscape of resected ALK-positive lung cancer and support CNS-active perioperative ALK-targeted strategies, particularly in patients with high-risk nodal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.